Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis
| Autor: | Xuejun Li, Ya-xin Yu, Wang Ly, Shuiyuan Yang, Wei Zhang, Hui Zhang, Zhang Sh, Changqin Liu, Bing Yan |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases business.industry Endocrinology Diabetes and Metabolism Placebo-controlled study nutritional and metabolic diseases medicine.disease Polycystic ovary law.invention Metformin chemistry.chemical_compound Endocrinology Dehydroepiandrosterone sulfate Randomized controlled trial chemistry law Diabetes mellitus Internal medicine medicine business Rosiglitazone Pioglitazone medicine.drug |
| Zdroj: | Clinical Endocrinology. 74:332-339 |
| ISSN: | 0300-0664 |
| DOI: | 10.1111/j.1365-2265.2010.03917.x |
| Popis: | Summary Objectives Insulin-sensitizing drugs (ISDs) have been advocated for the long-term treatment of polycystic ovary syndrome (PCOS). It is therefore important to compare the efficacy and safety of ISDs such as metformin and thiazolidinediones (TZDs) for the treatment of this syndrome. Methods A meta-analysis to assess the effectiveness and safety of metformin vs TZDs (including pioglitazone and rosiglitazone) in the treatment of PCOS was conducted, using MEDLINE (1966–May 2010) and EMBASE (1988–May 2010) to select randomized controlled trials comparing clinical, hormonal and metabolic results. Results Ten trials were included. TZDs were superior to metformin in reducing serum levels of free testosterone (P = 0·03) and dehydroepiandrosterone sulfate (DHEA) (P = 0·002) after 3 months treatment. Decreases in triglyceride levels were more pronounced with metformin after 6 months (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text